Fused tricyclic compounds as inhibitors of 17β-hydroxysteroid dehydrogenase 3
申请人:Bristol-Myers Squibb Company
公开号:US07417040B2
公开(公告)日:2008-08-26
Disclosed are fused tricyclic compounds of the following formula I,
or an enantiomer, diastereomer, tautomer or pharmaceutically acceptable salt thereof. The disclosed compounds are useful as inhibitors of 17β-hydroxysteriod dehydrogenase 3 (17βHSD3). Also disclosed are methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer and pharmaceutical compositions comprising such compounds.
FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF 17BETA-HYDROXYSTEROID DEHYDROGERNASE 3
申请人:Bristol-Myers Squibb Company
公开号:EP1720613A2
公开(公告)日:2006-11-15
EP1720613A4
申请人:——
公开号:EP1720613A4
公开(公告)日:2009-05-06
US7417040B2
申请人:——
公开号:US7417040B2
公开(公告)日:2008-08-26
[EN] FUSED TRICYCLIC COMPOUNDS AS INHIBITORS OF 17BETA-HYDROXYSTEROID DEHYDROGERNASE 3<br/>[FR] COMPOSES TRICYCLIQUES FUSIONNES EN TANT QU'INHIBITEURS DE 17BETA-HYDROXYSTEROIDE DESHYDROGENASE 3
申请人:BRISTOL MYERS SQUIBB CO
公开号:WO2005084296A2
公开(公告)日:2005-09-15
Fused tricyclic compounds, methods of using such compounds in the treatment of hormone sensitive diseases such as prostate cancer, and pharmaceutical compositions containing such compounds.